Reference | Country | Design | Outcome measure | Finding |
---|---|---|---|---|
SMS | ||||
Bediang et al. 2018 [37] | Cameroon | RCT: SMS vs DOT | Treatment success, cure | No significant difference |
Fang et al. 2017 [38] | China | RCT: SMS vs DOT | Treatment completion | High |
Mohammed et al. 2016 [39] | Pakistan | RCT: SMS vs DOT | Treatment success, cure | No significant difference |
Liu et al. 2015 [40] | China | RCT: 4 arms | Pill count, adherence | No significant improvement |
Iribarren et al. 2013 [41] | Argentina | Cross-sectional | Feasibility and acceptability | acceptable and feasible |
MERM | ||||
Onwubiko et al. 2019 [42] | USA | RCT: MERM vs DOT | Treatment completion | Low |
Park et al. 2019 [43] | Morocco | RCT: MERM vs DOT | Treatment success, cure | High |
Liu et al. 2017 [44] | China | Multi-method | User performance, satisfaction | High |
Broomhead et al. 2012 [45] | USA | Cross-sectional | Treatment outcome, cost | High, lower cost per patient |
Thakkar et al. 2019 [46] | India | Cohort, 99DOTS used | Treatment adherence | High |
VDOT | ||||
Lam et al. 2018 [47] | USA | RCT. VDOT vs DOT | Treatment completion | High |
Garfein et al. 2018 [48] | USA | RCT: VDOT vs DOT | Adherence, cost | High, lower cost |
Nguyen et al. 2017 [49] | Vietnam | Prospective cohort | Treatment adherence | High |
Chuck et al. 2016 [50] | USA | RCT: VDOT vs DOT | Treatment completion | High |
Garfein et al. 2015 [51] | USA, Mexico | Single-arm trial | Treatment adherence | High in both settings |